First Wave BioPharma Inc
NASDAQ:ENTO

Watchlist Manager
First Wave BioPharma Inc Logo
First Wave BioPharma Inc
NASDAQ:ENTO
Watchlist
Price: 2.63 USD -5.73% Market Closed
Market Cap: 8.8m USD

Relative Value

There is not enough data to reliably calculate the relative value of ENTO.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

ENTO Relative Value
Base Case
Not Available
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
7.8
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
24.1
Forward
-1.7
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
21.8
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
23.8
vs History
14
vs Industry
Median 3Y
0.1
Median 5Y
0
Industry
3.3
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
8
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
10.3
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
6.3
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
6.7
Forward
-0.3
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
7.9
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
6.3
vs History
17
vs Industry
Median 3Y
0.1
Median 5Y
0
Industry
5.5

Multiples Across Competitors

ENTO Competitors Multiples
First Wave BioPharma Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
First Wave BioPharma Inc
NASDAQ:ENTO
8.8m USD 0 -0.5 -2 -2
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 678 969.3 -160 071.1 -194 377.4 -192 159.4
US
Abbvie Inc
NYSE:ABBV
406.3B USD 6.8 173 16.7 23.7
US
Amgen Inc
NASDAQ:AMGN
179.7B USD 5 25.6 18.4 18.4
US
Gilead Sciences Inc
NASDAQ:GILD
156.1B USD 5.4 19.2 12.9 12.9
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
117.6B USD 10 32 23.5 24.5
US
Epizyme Inc
F:EPE
94.1B EUR 2 091.8 -533.8 -581.2 -565.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
82.5B USD 5.8 18 17.2 19.5
AU
CSL Ltd
ASX:CSL
83B AUD 3.6 18.5 12.5 15.6
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
52.8B USD 16.5 1 212.2 163.5 198.2
NL
argenx SE
XBRU:ARGX
44B EUR 14.4 33.8 58.2 59.8
P/E Multiple
Earnings Growth PEG
US
First Wave BioPharma Inc
NASDAQ:ENTO
Average P/E: 191.6
Negative Multiple: -0.5
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 071.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
173
89%
1.9
US
Amgen Inc
NASDAQ:AMGN
25.6
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
19.2
190%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
32
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -533.8 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18
9%
2
AU
CSL Ltd
ASX:CSL
18.5
11%
1.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
1 212.2
N/A N/A
NL
argenx SE
XBRU:ARGX
33.8
40%
0.8
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
First Wave BioPharma Inc
NASDAQ:ENTO
Average EV/EBITDA: 40.4
Negative Multiple: -2
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 377.4 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.7
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
18.4
11%
1.7
US
Gilead Sciences Inc
NASDAQ:GILD
12.9
7%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.5
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -581.2 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.2
11%
1.6
AU
CSL Ltd
ASX:CSL
12.5
8%
1.6
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
163.5
N/A N/A
NL
argenx SE
XBRU:ARGX
58.2
807%
0.1
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
First Wave BioPharma Inc
NASDAQ:ENTO
Average EV/EBIT: 46.6
Negative Multiple: -2
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -192 159.4 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.7
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
18.4
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.9
12%
1.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.5
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -565.7 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
19.5
13%
1.5
AU
CSL Ltd
ASX:CSL
15.6
11%
1.4
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
198.2
N/A N/A
NL
argenx SE
XBRU:ARGX
59.8
N/A N/A